132 related articles for article (PubMed ID: 16958135)
41. Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapy.
Negro F
Gut; 2010 Dec; 59(12):1590-1. PubMed ID: 20926646
[No Abstract] [Full Text] [Related]
42. Host cell targets in HCV therapy: novel strategy or proven practice?
Klebl BM; Kurtenbach A; Salassidis K; Daub H; Herget T
Antivir Chem Chemother; 2005; 16(2):69-90. PubMed ID: 15889531
[TBL] [Abstract][Full Text] [Related]
43. [Treatment of chronic hepatitis C. The Danish Society of Infection Medicine].
Weis NM; Christensen PB; Laursen AL
Ugeskr Laeger; 2006 Mar; 168(12):1221. PubMed ID: 16571312
[No Abstract] [Full Text] [Related]
44. Targeting host factors: a novel rationale for the management of hepatitis C virus.
Khattab MA
World J Gastroenterol; 2009 Jul; 15(28):3472-9. PubMed ID: 19630100
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms and Consequences of Genetic Variation in Hepatitis C Virus (HCV).
Galli A; Bukh J
Curr Top Microbiol Immunol; 2023; 439():237-264. PubMed ID: 36592248
[TBL] [Abstract][Full Text] [Related]
46. [New therapies for hepatitis C].
Gil-Guerrero L; Sarobe P; Prieto J
Med Clin (Barc); 2006 Jun; 127(3):104-12. PubMed ID: 16828002
[TBL] [Abstract][Full Text] [Related]
47. New therapeutic approaches to hepatitis C virus.
Sakamoto N; Watanabe M
J Gastroenterol; 2009; 44(7):643-9. PubMed ID: 19455277
[TBL] [Abstract][Full Text] [Related]
48. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection?
Bowen DG; Walker CM
J Hepatol; 2005 Mar; 42(3):408-17. PubMed ID: 15710225
[No Abstract] [Full Text] [Related]
49. [Hepatitis C. How can we eradicate the definitive virus?].
Melman ML
Rev Gastroenterol Mex; 2004 Nov; 69 Suppl 3():138-9. PubMed ID: 16881218
[No Abstract] [Full Text] [Related]
50. The Role of MicroRNA in Hepatitis C Virus Replication.
Duan XQ; Li SL; Li YJ; Liu B; Zeng PB; Yang CH; Chen LM
J Clin Transl Hepatol; 2013 Dec; 1(2):125-30. PubMed ID: 26355873
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C Virus: Evading the Intracellular Innate Immunity.
Ferreira AR; Ramos B; Nunes A; Ribeiro D
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183176
[TBL] [Abstract][Full Text] [Related]
52. [Diagnostics and therapy of hepatitis].
Strassburg CP; Cornberg M
Internist (Berl); 2009 Dec; 50(12):1358-68. PubMed ID: 19921110
[TBL] [Abstract][Full Text] [Related]
53. Fighting hepatitis C virus with peptide nanotubes.
Brik A
Chem Biol; 2011 Nov; 18(11):1347-8. PubMed ID: 22118665
[TBL] [Abstract][Full Text] [Related]
54. QUEST for a cure for hepatitis C virus: the end is in sight.
Ghany MG; Gara N
Lancet; 2014 Aug; 384(9941):381-3. PubMed ID: 24907223
[No Abstract] [Full Text] [Related]
55. Structural biology of the hepatitis C virus proteins.
Drug Discov Today Technol; 2012; 9(3):e175-226. PubMed ID: 24064309
[No Abstract] [Full Text] [Related]
56. [An effective culture system for hepatitis C virus in sight].
Morice Y
Virologie (Montrouge); 2005 Oct; 9(5):414-415. PubMed ID: 34679289
[No Abstract] [Full Text] [Related]
57. Illustrated overview of vital cycle of Hepatitis C virus.
Poulot A; Penin F
Virologie (Montrouge); 2016 Feb; 20(1):E1-E31. PubMed ID: 33065857
[No Abstract] [Full Text] [Related]
58. Prevalence of Hepatitis B and Hepatitis C Viral Infections and Their Associated Factors among Diabetic Patients Visiting Debre Tabor Referral Hospital, Northwest Ethiopia, 2021: A Cross-Sectional Study.
Belete D; Kassaw D; Andualem T
Can J Gastroenterol Hepatol; 2023; 2023():5077706. PubMed ID: 38021268
[TBL] [Abstract][Full Text] [Related]
59. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
